Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial

Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection. Design, Settin...

Full description

Saved in:
Bibliographic Details
Main Authors: Batran, Salah-Eddin al- (Author) , Post, Stefan (Author) , Ronellenfitsch, Ulrich (Author) , Hofheinz, Ralf-Dieter (Author)
Format: Article (Journal)
Language:English
Published: September 2017
In: JAMA oncology
Year: 2017, Volume: 3, Issue: 9, Pages: 1237-1244
ISSN:2374-2445
DOI:10.1001/jamaoncol.2017.0515
Online Access:Verlag, Volltext: http://dx.doi.org/10.1001/jamaoncol.2017.0515
Verlag, Volltext: https://jamanetwork.com/journals/jamaoncology/fullarticle/2621996
Get full text
Author Notes:Salah-Eddin Al-Batran, MD, Nils Homann, MD, Claudia Pauligk, PhD, Gerald Illerhaus, MD, Uwe M. Martens, MD, Jan Stoehlmacher, MD, Harald Schmalenberg, MD, Kim B. Luley, MD, Nicole Prasnikar, MD, Matthias Egger, MD, Stephan Probst, MD, Helmut Messmann, MD, Markus Moehler, MD, Wolfgang Fischbach, MD, Jörg T. Hartmann, MD, Frank Mayer, MD, Heinz-Gert Höffkes, MD, Michael Koenigsmann, MD, Dirk Arnold, MD, Thomas W. Kraus, MD, Kersten Grimm, MD, Stefan Berkhoff, MD, Stefan Post, MD, Elke Jäger, MD, Wolf Bechstein, MD, Ulrich Ronellenfitsch, MD, Stefan Mönig, MD, Ralf D. Hofheinz, MD

MARC

LEADER 00000caa a22000002c 4500
001 1582154503
003 DE-627
005 20230427193146.0
007 cr uuu---uuuuu
008 181022s2017 xx |||||o 00| ||eng c
024 7 |a 10.1001/jamaoncol.2017.0515  |2 doi 
035 |a (DE-627)1582154503 
035 |a (DE-576)512154503 
035 |a (DE-599)BSZ512154503 
035 |a (OCoLC)1341020408 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Batran, Salah-Eddin al-  |e VerfasserIn  |0 (DE-588)114597359  |0 (DE-627)626875730  |0 (DE-576)323432840  |4 aut 
245 1 0 |a Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer  |b the AIO-FLOT3 trial  |c Salah-Eddin Al-Batran, MD, Nils Homann, MD, Claudia Pauligk, PhD, Gerald Illerhaus, MD, Uwe M. Martens, MD, Jan Stoehlmacher, MD, Harald Schmalenberg, MD, Kim B. Luley, MD, Nicole Prasnikar, MD, Matthias Egger, MD, Stephan Probst, MD, Helmut Messmann, MD, Markus Moehler, MD, Wolfgang Fischbach, MD, Jörg T. Hartmann, MD, Frank Mayer, MD, Heinz-Gert Höffkes, MD, Michael Koenigsmann, MD, Dirk Arnold, MD, Thomas W. Kraus, MD, Kersten Grimm, MD, Stefan Berkhoff, MD, Stefan Post, MD, Elke Jäger, MD, Wolf Bechstein, MD, Ulrich Ronellenfitsch, MD, Stefan Mönig, MD, Ralf D. Hofheinz, MD 
264 1 |c September 2017 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published Online: April 27, 2017 
500 |a Gesehen am 22.10.2018 
520 |a Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection. Design, Setting, and Participants: The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Patients were enrolled from 52 cancer care centers in Germany between February 1, 2009, and January 31, 2010, and stratified to 1 of 3 groups: resectable (arm A), limited metastatic (arm B), or extensive metastatic (arm C). Data cutoff was January 2012, and the analysis was performed in March 2013. Interventions: Patients in arm A received 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgery and 4 postoperative cycles. Patients in arm B received at least 4 cycles of neoadjuvant FLOT and proceeded to surgical resection if restaging (using computed tomography and magnetic resonance imaging) showed a chance of margin-free (R0) resection of the primary tumor and at least a macroscopic complete resection of the metastatic lesions. Patients in arm C were offered FLOT chemotherapy and surgery only if required for palliation. Patients received a median (range) of 8 (1-15) cycles of FLOT. Main Outcomes and Measures: The primary end point was overall survival.Results: In total, 238 of 252 patients (94.4%) were eligible to participate. The median (range) age of participants was 66 (36-79) years in arm A (n = 51), 63 (28-79) years in arm B (n = 60), and 65 (23-83) years in arm C (n = 127). Patients in arm B (n = 60) had only retroperitoneal lymph node involvement (27 patients [45%]), liver involvement (11 [18.3%]), lung involvement (10 [16.7%]), localized peritoneal involvement (4 [6.7%]), or other (8 [13.3%]) incurable sites. Median overall survival was 22.9 months (95% CI, 16.5 to upper level not achieved) for arm B, compared with 10.7 months (95% CI, 9.1-12.8) for arm C (hazard ratio, 0.37; 95% CI, 0.25-0.55) (P<.001). The response rate for arm B was 60% (complete, 10%; partial, 50%), which is higher than the 43.3% for arm C. In arm B, 36 of 60 patients (60%) proceeded to surgery. The median overall survival was 31.3 months (95% CI, 18.9-upper level not achieved) for patients who proceeded to surgery and 15.9 months (95% CI, 7.1-22.9) for the other patients. Conclusions and Relevance: Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival. The AIO-FLOT3 trial provides a rationale for further randomized clinical trials. Trial Registration: clinicaltrials.gov identifier:NCT00849615 
700 1 |a Post, Stefan  |d 1954-  |e VerfasserIn  |0 (DE-588)1026227518  |0 (DE-627)726294667  |0 (DE-576)371524598  |4 aut 
700 1 |a Ronellenfitsch, Ulrich  |d 1977-  |e VerfasserIn  |0 (DE-588)13178322X  |0 (DE-627)513952179  |0 (DE-576)29874144X  |4 aut 
700 1 |a Hofheinz, Ralf-Dieter  |d 1969-  |e VerfasserIn  |0 (DE-588)121917517  |0 (DE-627)08161876X  |0 (DE-576)292991568  |4 aut 
773 0 8 |i Enthalten in  |t JAMA oncology  |d Chicago, Ill. : American Medical Association, 2015  |g 3(2017), 9, Seite 1237-1244  |h Online-Ressource  |w (DE-627)818494301  |w (DE-600)2810928-4  |w (DE-576)426501284  |x 2374-2445  |7 nnas  |a Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer the AIO-FLOT3 trial 
773 1 8 |g volume:3  |g year:2017  |g number:9  |g pages:1237-1244  |g extent:8  |a Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer the AIO-FLOT3 trial 
856 4 0 |u http://dx.doi.org/10.1001/jamaoncol.2017.0515  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://jamanetwork.com/journals/jamaoncology/fullarticle/2621996  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181022 
993 |a Article 
994 |a 2017 
998 |g 121917517  |a Hofheinz, Ralf-Dieter  |m 121917517:Hofheinz, Ralf-Dieter  |d 60000  |d 61200  |e 60000PH121917517  |e 61200PH121917517  |k 0/60000/  |k 1/60000/61200/  |p 28  |y j 
998 |g 13178322X  |a Ronellenfitsch, Ulrich  |m 13178322X:Ronellenfitsch, Ulrich  |d 910000  |d 910200  |e 910000PR13178322X  |e 910200PR13178322X  |k 0/910000/  |k 1/910000/910200/  |p 26 
998 |g 1026227518  |a Post, Stefan  |m 1026227518:Post, Stefan  |d 60000  |d 61800  |e 60000PP1026227518  |e 61800PP1026227518  |k 0/60000/  |k 1/60000/61800/  |p 23 
999 |a KXP-PPN1582154503  |e 3029401685 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Salah-Eddin Al-Batran, MD, Nils Homann, MD, Claudia Pauligk, PhD, Gerald Illerhaus, MD, Uwe M. Martens, MD, Jan Stoehlmacher, MD, Harald Schmalenberg, MD, Kim B. Luley, MD, Nicole Prasnikar, MD, Matthias Egger, MD, Stephan Probst, MD, Helmut Messmann, MD, Markus Moehler, MD, Wolfgang Fischbach, MD, Jörg T. Hartmann, MD, Frank Mayer, MD, Heinz-Gert Höffkes, MD, Michael Koenigsmann, MD, Dirk Arnold, MD, Thomas W. Kraus, MD, Kersten Grimm, MD, Stefan Berkhoff, MD, Stefan Post, MD, Elke Jäger, MD, Wolf Bechstein, MD, Ulrich Ronellenfitsch, MD, Stefan Mönig, MD, Ralf D. Hofheinz, MD"]},"person":[{"family":"Batran","display":"Batran, Salah-Eddin al-","role":"aut","given":"Salah-Eddin al-"},{"family":"Post","display":"Post, Stefan","role":"aut","given":"Stefan"},{"family":"Ronellenfitsch","role":"aut","given":"Ulrich","display":"Ronellenfitsch, Ulrich"},{"given":"Ralf-Dieter","role":"aut","display":"Hofheinz, Ralf-Dieter","family":"Hofheinz"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1582154503","origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"September 2017"}],"note":["Published Online: April 27, 2017","Gesehen am 22.10.2018"],"relHost":[{"pubHistory":["1.2015 -"],"language":["eng"],"part":{"text":"3(2017), 9, Seite 1237-1244","year":"2017","volume":"3","issue":"9","pages":"1237-1244","extent":"8"},"title":[{"title_sort":"JAMA oncology","title":"JAMA oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"818494301","origin":[{"publisherPlace":"Chicago, Ill.","dateIssuedKey":"2015","publisher":"American Medical Association","dateIssuedDisp":"2015-"}],"note":["Gesehen am 12.10.2017"],"corporate":[{"role":"isb","display":"American Medical Association"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer the AIO-FLOT3 trialJAMA oncology","id":{"eki":["818494301"],"zdb":["2810928-4"],"issn":["2374-2445"]}}],"physDesc":[{"extent":"8 S."}],"id":{"eki":["1582154503"],"doi":["10.1001/jamaoncol.2017.0515"]},"language":["eng"],"title":[{"title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer","subtitle":"the AIO-FLOT3 trial","title_sort":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer"}]} 
SRT |a BATRANSALAEFFECTOFNE2017